WO1999028441A1 - Nouvelle souche de bacillus subtilis avec effets antibacteriens - Google Patents

Nouvelle souche de bacillus subtilis avec effets antibacteriens Download PDF

Info

Publication number
WO1999028441A1
WO1999028441A1 PCT/JP1998/005404 JP9805404W WO9928441A1 WO 1999028441 A1 WO1999028441 A1 WO 1999028441A1 JP 9805404 W JP9805404 W JP 9805404W WO 9928441 A1 WO9928441 A1 WO 9928441A1
Authority
WO
WIPO (PCT)
Prior art keywords
bacillus subtilis
strain
bacillus
cell component
live
Prior art date
Application number
PCT/JP1998/005404
Other languages
English (en)
Japanese (ja)
Inventor
Seiichi Araki
Mamoru Suzuki
Original Assignee
Eisai Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co., Ltd. filed Critical Eisai Co., Ltd.
Priority to AU12631/99A priority Critical patent/AU1263199A/en
Publication of WO1999028441A1 publication Critical patent/WO1999028441A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus

Definitions

  • the present invention relates to an antibacterial agent containing a novel Bacillus subtilis strain as an active ingredient. More specifically, the present invention relates to an antibacterial agent containing, as an active ingredient, an AS 2 strain, which is a kind of Bacillus subtilis, ie, a strain of Bacillus subtilis.
  • AS 2 strain which is a kind of Bacillus subtilis, ie, a strain of Bacillus subtilis.
  • antibiotics such as antibacterial agents and antifungal agents are effective for the prevention and treatment of various infectious diseases, and they have been widely used in clinical settings to date. These antibiotics can be obtained by extracting those produced by bacteria or fungi, or by chemically synthesizing them. However, repeated use of the same family of antibiotics for a long period of time causes the bacteria to acquire resistance, and the effect cannot be exhibited even if the drug is administered. Has become.
  • Penicillin-notysum Penicillium notatum
  • Penicillin-chrysogenum P. chrysogenum
  • penicillin has bacteriostatic and bactericidal effects against Gram-positive bacteria, and thus has a problem in selectivity.
  • Another problem is that a wide range of bacteria acquire resistance to penicillin.
  • Bacillus subtilis as a microorganism that produces a substance having a selective spectrum Bacteria such as squirrels (Bacillus subtilis) and Bacillus lichen iformis are known. Have reported that Bacillus' licheniformis secretes bacitracin, which suppresses the growth of Clostridium perfringens (Ducluzeau, R., et al., Antimicrobial agents and Chemotherapy, 9). , 20-25, 1976). In addition, Japanese Patent Publication No. 8-18996 discloses a strain containing Bacillus subtilis IF0-3009, IF0-3013, IF0-3335, IF0-3336, IFO-3936 and IF0-13169.
  • Bacillus subtilis TSMPM No. V- 2335 reported against Pseudomonas aeruginosa, Shigella Sonny, Salmonella, Klebsiella Numonya, and Proteus Bulgaris.
  • Bacillus licheniformis '' TSMPM No. V-233 6 is Staphylococcus aureus, Candida albican, Aspergillus
  • AS 2 strain which is a kind of Bacillus subtilis, has been transformed into Salmonella, Escherichia coli, Staphylococcus, Vibrio parahaemolyticus, Shows stronger antibacterial activity against various harmful bacteria such as Campylobacter, B. borinus, and Welsh than conventional bacterial strains, and does not act on useful bacteria such as lactic acid bacteria and Bacillus natto. And completed the present invention.
  • the present invention relates to 1) that it has lactose and amygdalin utilization ability and does not have inulin utilization ability, that orthonitrophenol-] 3-D-galactopyranoside test is negative, Bacillus subtilis AS2 strain (Bacillus subtilis AS2), characterized by non-growth, accession number FERM BP-6139, 2) Bacillus subtilis having the base sequence of 16 S ribosomal RNA shown in SEQ ID NO: 1 AS 2 strain (Bacillus subtilis AS2), accession number FE RM BP-6139, 3) An antibacterial agent containing a living bacterium, a dead bacterium or a cell component of the AS 2 strain as an active ingredient, 4) Food containing the antibacterial agent, 5) Feed for livestock or farmed fish containing the antibacterial agent, 6) Preventive and therapeutic agent for infectious diseases containing 2 strains of AS, 7) Antidiarrhea, intestinal medicine containing 2 strains of AS, 8) Deodorization of f
  • Bacillus subtilis AS2 strain was deposited with the Institute of Biotechnology and Industrial Technology (FERM), 1-3 1-3 Higashi, Tsukuba, Ibaraki, Japan on October 9, 1997. The deposit number is FERM BP-6139.
  • FERM Institute of Biotechnology and Industrial Technology
  • Bacillus subtilis AS2 strain may be abbreviated as Bacillus subtilis AS2 strain or AS2 strain.
  • the Bacillus subtilis AS2 strain according to the present invention has the following properties.
  • 0-ditrophenol-1 / 3-D-galactopyranoside does not grow at 50, or has lactose and amygdalin utilization ability, and has no inulin utilization ability. This is a new strain with different properties from general Bacillus * subtilis.
  • AS 2 strain has the nucleotide sequence shown in SEQ ID NO: 1 as 16S ribosomal RNA. Have. Some nucleotides may be substituted / added / deleted to the extent that their properties do not substantially change.
  • the present invention provides a live cell, a dead cell, or a cell component of the Bacillus subtilis described above.
  • An antibacterial agent containing the cell component as an active ingredient is also provided.
  • an excipient that enhances the action and an antibacterial composition containing the antibacterial agent are provided, and yeast is preferable as the excipient.
  • the present invention provides an immunopotentiator comprising the above-mentioned bacterial cell component as an active ingredient, an antibacterial method by applying an antibacterial effective amount of the above-mentioned bacterial cell component to a place requiring antibacterial, A method for preventing or treating infectious diseases by administering an effective amount to humans or animals; a method for enhancing immunity by administering an effective amount of the above-mentioned bacterial cell components to humans or animals; A method of preventing or treating diarrhea by administering an effective amount to humans or animals, or a method of intestinal detoxification; a method of administering an effective amount of the above-mentioned bacterial cell components to humans or animals to deodorize feces; A method of promoting growth by administering an effective amount of a body component to a human or an animal, a method of administering an effective amount of the above-mentioned bacterial body component to a human or an animal, and reducing side effects associated with administration of an anticancer agent; Edible products containing the above antibacterial agent and food
  • Escherichia coli including pathogenic Escherichia coli such as intestinal hemorrhagic
  • Clostridium periinge C. chauvoei
  • Clostridium porulinum C. botulinum
  • Clostridium 'C. tetani Clostridium, septicum, etc.
  • genus Clostridium, Campylobacter fetutus Campylobacter fetus
  • Campiropactor jejuni
  • Ki Campylobacter species such as C. sputorum, C. mucosalis, C. mucosal is, iaecalis, Yersinia pestis, Elelesinia 'Sh——D. Berberekulosis, Y.
  • enterocolitica etc.
  • Genus L. genus such as Enterobactor cloacae, Enterobactor cloacae, etc.
  • Citrobacter such as Citrobacter freundii
  • Proteus Proteus
  • Bacteroides and Fusobacterium.
  • it exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus ⁇ MRS A, macrolide-resistant Enterococcus 'Seriolicida', and Escherichia coli serotypes 026 and 011K ⁇ 157.
  • this strain is a genus of Bifidobacterium such as Biiidobacterium longum, Bifidobacterium bifidum, Bifidobacterium 'B. breve, or Lactobacillus bulgarium. Lactobacillus (Lactobacil lus bulgaricus), Lactobacillus genus such as Lactobacillus'acidophilus' (L. acidphi lus), Streptococcus' thermophilus (Streptococcus thermophi lus) etc. It does not show antibacterial activity against useful bacteria such as Bacillus such as Bacillus subtilis).
  • the method for administering the antibacterial agent according to the present invention includes oral administration, or a method of ingesting it in a food, feed, drinking water, etc., depending on the purpose of administration and conditions such as symptoms.
  • the antibacterial agent according to the present invention may be administered as a living bacterium or in a dead bacterium state. Even if the cells have been decomposed by freezing, heating, drying, exposure to drugs, etc., the components may be retained as long as the components are retained.
  • powders, tablets, granules, capsules, liquids can be prepared by known methods, and can be mixed with foods, feeds, drinking water, and the like, according to commonly used carriers for preparations.
  • excipients When preparing oral formulations, excipients, binders, binders, disintegrators, lubricants, coloring agents, flavoring agents, antioxidants, solubilizing agents, etc. Tablets, coated tablets, granules, powders, capsules, etc. are made in the usual manner.
  • excipients include starch, corn starch, dextrin, yeast extract powder, flour, wheat middling, bran, rice bran, rice bran oil residue, soybean residue, soybean powder, soybean oil residue, kinako, glucose, lactose, White sugar, maltose, vegetable oil, animal oil, hydrogenated oil, higher saturated fatty acid, fatty acid, mannitol, crystalline cellulose, Silicon dioxide, anhydrous silicon, calcium silicate, silicic acid, calcium monohydrogen phosphate, dibasic calcium phosphate, tricalcium phosphate, calcium phosphate, dibasic calcium phosphate and the like are used.
  • Binders include polyvinylpyrrolidone, ethylcellulose, methylcellulose, gum arabic, tragacanth, hydroxypropylcellulose, hydroxypropylmethylcellulose, sodium alginate, sodium caseinate, sodium propyloxymethylcellulose, propylene glycol, sodium polyacrylate Are used.
  • Magnesium stearate, talc, stearic acid and the like are used as lubricants.
  • the coloring agent and flavoring agent are not particularly limited as long as they are permitted to be added to pharmaceuticals and feeds. Any antioxidants such as ascorbic acid, ⁇ -tocopherol, ethoxyquin, dibutylhydroxytoluene, and butylhydroxyanisole are permitted if they are allowed to be added to pharmaceuticals and feeds. ⁇ Tablets and granules are required It may be coated according to.
  • ⁇ preparation When preparing a liquid formulation, add ⁇ preparation, buffer, suspending agent, solubilizing agent, stabilizer, isotonic agent, antioxidant, preservative, etc. It can be manufactured by a conventional method. In this case, if necessary, a freeze-dried agent can be used.
  • the culturing of the Bacillus subtilis AS2 strain according to the present invention may be performed by a commonly used method.
  • agar medium for example, agar medium, blood agar medium, heart infusion medium, tryptophan medium, Sabouraud agar medium, brain heart infusion liquid medium, etc. under aerobic conditions at a culture temperature of 10 to 45, pH 5 to 8, etc. It can be easily cultured in any medium.
  • FIG. 1 shows the action of Bacillus * subtilis ⁇ AS2 strain on Escherichia coli.
  • FIG. 2 is a diagram showing the action of Bacillus subtilis natto strain on Escherichia coli.
  • FIG. 3 is a diagram showing the bactericidal action of Bacillus subtilis AS2 strain, IF0-3009 strain, and PCI219 strain on Escherichia coli.
  • FIG. 4 is a diagram showing the bactericidal action of Bacillus subtilis AS2 strain, IF0-3009 strain, and PCI219 strain on Salmonella.
  • Bacillus subtilis AS2 strain shows that Salmonella, Escherichia, Enterobacter, Serratia, Proteus, It has been found that it has an antibacterial activity against bacteria such as Staphylococcus, Enterococcus, Clostridium and the like, and does not act on useful bacteria such as Bifidobacterium and Bacillus natto.
  • Bacillus subtilis AS2 against enterohemorrhagic Escherichia coli, Staphylococcus aureus, Bacillus * cereus, Vibrio parahaemolyticus, and Yersinia enterocolitica was examined by cross streaking.
  • the bacteria shown in Table 2 were inoculated linearly onto a Murat-Hinton agar medium, and then the AS2 strain was inoculated linearly so as to cross each other, and cultured at 37 for 24 hours. Thereafter, the growth of general bacteria at the intersection was observed. Table 2 shows the results.
  • Bacillus subtilis AS2 strain according to the present invention has an antibacterial activity against various food poisoning-related bacteria such as intestinal bleeding Escherichia coli and Vibrio parahaemolyticus.
  • Example 3 Sterilization of Escherichia coli by strain AS2
  • Bacillus subtilis ⁇ AS 2 strain on Escherichia coli ⁇ E01292 strain was examined.
  • Bacillus subtilis' nut which is a commercially available natto fungus was used.
  • Escherichia coli is pre-cultured in Brain 'Heart' Infusion (hereinafter referred to as BHI) 'broth medium (BBL) at 37 for 18 hours, and inoculated individually or together with two AS strains into 30 ml of BHI medium in a 100 ml flask. And shaking culture in a water bath at 37. Sampling before, after 1, 2 and 3 days before the start of the mixed culture, creating a 10-fold serial dilution series with physiological saline, of which 0.1 ml was spread on an agar medium and cultured for 24 hours at 37 ⁇ : The number was measured.
  • BHI Brain 'Heart' Infusion
  • BBL Brain 'Heart' Infusion
  • MacConkey agar medium manufactured by BBL was used for separation of Escherichia coli
  • Sabouraud agar medium manufactured by Nissui Pharmaceutical
  • FIGS. 1 and 2 The results are shown in FIGS. 1 and 2.
  • the number of Escherichia coli mixed and cultured with the AS2 strain decreased from 1 day after the start of the culture, whereas the number of Escherichia coli mixed and cultured with Bacillus natto showed no change.
  • Bacillus subtilis ⁇ AS 2 strain The bactericidal effect of Bacillus subtilis ⁇ AS 2 strain on Escherichia coli ⁇ NIHJ strain and Salmonella enteritidis ⁇ ATCC 14028 strain was examined. As controls, Bacillus subtilis B. subtilis IF0-3009 strain and Bacillus subtilis PC1219 strain were used.
  • Escherichia coli and Salmonella were pre-cultured in BHI broth medium (manufactured by BBL) at 37 for 18 hours, and inoculated individually or together with AS2 strain into 30 ml of BHI medium in lOOml flask, and cultured with shaking in a water bath of 37 did. Sampling before, 1 and 3 days after the start of cultivation, making a 10-fold serial dilution series with physiological saline, of which 0.1 ml was spread on an agar medium and cultured at 37 for 24 hours The number of bacteria was counted.
  • Example 5 Adherence to the intestinal tract when artificially ingesting 2 strains of AS
  • mice each 10 examples of male mice (SLC: ICR, 5 weeks old) for 3 consecutive days orally AS 2 strain 107, 10 8 or 10 9 CFU / 0.5 ml suspended in physiological saline, final dose human derived from Escherichia coli E01292 strain 4.0xl0 7 CFU / 0.2ml suspended in physiological saline after 24 hours was given intravenously throw.
  • the survival rate of the mice 4 days after the inoculation was calculated to determine the protective effect.
  • prophylactic administration of the AS2 strain enhanced the infection resistance of the mice to E. coli infection, and showed a significant increase in the survival rate as compared with the control group. That is, it was suggested that the AS 2 strain exhibited an immunopotentiating effect (Table 4).
  • mice each 10 examples of male mice (SLC: ICR, 5 weeks old) and AS 2 strain 10 ⁇ 10 8 or 10 9 CFU / 0.5 ml of 6 consecutive days orally suspended in physiological saline, administered 4 days the ⁇ Shi mastitis from Staphylococcus aureus OB- 72 strain 6.5xi0 7 CFU / 0.2ml suspended in physiological saline salt solution was administered vein in eyes.
  • the survival rate of mice 7 days after the last AS 2 strain administration was calculated to determine the protective effect (Table 5).
  • Table 5 A'tils-fu 'published by' AS2 strain against yellow-feast V. aureus
  • mice Group each 10 examples of male mice (SLC: ICR, 5 weeks old) were orally administered AS 2 shares 10 ⁇ 10 8 or 10 9 CFU / 0.5 ml suspended in physiological saline, E. coli LPS 50 after 24 hours mg / kg was administered into the tail vein, and 6 hours later, the same dose of each of the AS2 strains was orally administered.
  • the survival rate of mice 4 days after inoculation of the LPS solution was calculated, and the protective effect was determined (Table 7).
  • Table 7 Protective effect of Ha'tilus-s'fu'tilis-AS2 strain against endotoxin
  • Example 1 Deodorizing effect of 2 AS 2 strains on chicken dung
  • strain AS2 showed a deodorizing effect on chicken dung (Table 9).
  • Table 9 Deodorizing effect of C'tils's'fu'tilis-AS2 strain
  • mice Group each five cases of male mice (SLC: ICR, 3 weeks old, weight 10-12 g) in, 3.125Xl0 4, the 1.25x 10 5, 5 X 10 5 or 2X 10 concentration AS 2 strain of 6 CFU / g
  • the mice were bred for 28 days with the added mouse feed (trade name: MF, Oriental Yeast Co., Ltd.), and the weight gain and weight gain were calculated.
  • the body weight gain effect was observed in a dose-dependent manner in all cases as compared with the control group (Table 10).
  • Ribosomal-RNA 16S was converted to Microsec 16Sr RNA Gene kit (trade name, (Applied Biosystems). That is, after collecting and lysing the colonies on the flat plate of each strain, preparing type I, amplifying by the PCR method, and using an ABI plasma 310 Genetic analyzer (trade name, manufactured by Perkin Elma Inc.) A sequence was performed.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Insects & Arthropods (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Birds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une nouvelle souche de Bacillus subtilis, et plus particulièrement une souche de Bacillus subtilis AS2 (numéro d'ordre: FERM BP-6139), dont les caractéristiques présentent des effets antibactériens puissants contre les bactéries nuisibles des genres Salmonella, Escherichia, Shigella, Vibrio, Staphylococcus, Clostridium, et Campylobacter. Cette souche reste néanmoins sans effets sur les bactéries lactiques des genres Bifibacterium, Lactobacillus, et Bacillus natto.
PCT/JP1998/005404 1997-12-01 1998-12-01 Nouvelle souche de bacillus subtilis avec effets antibacteriens WO1999028441A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU12631/99A AU1263199A (en) 1997-12-01 1998-12-01 Novel (bacillus subtilis) with antibacterial effects

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33002197 1997-12-01
JP9/330021 1997-12-01

Publications (1)

Publication Number Publication Date
WO1999028441A1 true WO1999028441A1 (fr) 1999-06-10

Family

ID=18227896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/005404 WO1999028441A1 (fr) 1997-12-01 1998-12-01 Nouvelle souche de bacillus subtilis avec effets antibacteriens

Country Status (2)

Country Link
AU (1) AU1263199A (fr)
WO (1) WO1999028441A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062093A1 (fr) * 2000-02-23 2001-08-30 Kureha Chemical Industry Co., Ltd. Promoteurs de croissance des plantes et procede de promotion de la croissance des plantes
WO2004050832A2 (fr) 2002-11-27 2004-06-17 Kemin Industries, Inc. Composes anti-microbiens issus de bacillus subtilis et a utiliser contre des pathogenes animaux et humains
WO2005007833A1 (fr) * 2003-07-17 2005-01-27 Charles Sturt University Isolat de souche de bacille a activite de suppression fongique
WO2017132230A1 (fr) * 2016-01-25 2017-08-03 Novozymes A/S Procédé pour réduire la prolifération microbienne dans un couvoir à volailles
WO2021234102A1 (fr) * 2020-05-20 2021-11-25 Nolivade Procédé de décontamination

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63273470A (ja) * 1987-01-21 1988-11-10 アグリカルチュラル、ジェネティックス、カンパニー、リミテッド 抗菌活性を有する微生物菌株
JPH01121219A (ja) * 1987-10-31 1989-05-12 Karupisu Shokuhin Kogyo Kk 抗クロストリジウム生菌剤
JPH04166080A (ja) * 1990-10-31 1992-06-11 Korea Res Inst Chem Technol 新規なバシラス・サブチリス亜種およびそれから生産される抗真菌物質ｋｒｆ―００１複合体
JPH04169191A (ja) * 1990-10-31 1992-06-17 Korea Res Inst Chem Technol 新規な抗真菌物質ｋｒｆ―００１複合体の発酵および精製方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63273470A (ja) * 1987-01-21 1988-11-10 アグリカルチュラル、ジェネティックス、カンパニー、リミテッド 抗菌活性を有する微生物菌株
JPH01121219A (ja) * 1987-10-31 1989-05-12 Karupisu Shokuhin Kogyo Kk 抗クロストリジウム生菌剤
JPH04166080A (ja) * 1990-10-31 1992-06-11 Korea Res Inst Chem Technol 新規なバシラス・サブチリス亜種およびそれから生産される抗真菌物質ｋｒｆ―００１複合体
JPH04169191A (ja) * 1990-10-31 1992-06-17 Korea Res Inst Chem Technol 新規な抗真菌物質ｋｒｆ―００１複合体の発酵および精製方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CUMMINGS N.J. et al., "The Bacillus Subtilis 168 Chromosome from sspE to katA", MICROBIOLOGY, (June 1997), Vol. 143, No. 6, p. 1855-1859. *
KUNST F. et al., "The Complete Genome Sequence of the Gram-Positive Bacterium Bacillus Subtilis", NATURE, (November 1997), Vol. 390, No. 20, p. 249-256. *
LIU H. et al., "Sequence and Analysis of a 31 Kb Segment of the Bacillus Subtilis Chromosome in the Area of the rrnH and rrnG Operons", MICROBIOLOGY, (August 1997), Vol. 143, No. 8, p. 2763-2767. *
YASUMOTO K. et al., "Sequence Analysis of a 50 Kb Region Between spoOH and rrnH on the Bacillus Subtilis Chromosome", MICROBIOLOGY, (1996), Vol. 142, No. 11, p. 3039-3046. *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062093A1 (fr) * 2000-02-23 2001-08-30 Kureha Chemical Industry Co., Ltd. Promoteurs de croissance des plantes et procede de promotion de la croissance des plantes
WO2004050832A2 (fr) 2002-11-27 2004-06-17 Kemin Industries, Inc. Composes anti-microbiens issus de bacillus subtilis et a utiliser contre des pathogenes animaux et humains
EP1576120A2 (fr) * 2002-11-27 2005-09-21 Kemin Industries, Inc. Composes anti-microbiens issus de i bacillus subtilis /i et a utiliser contre des pathogenes animaux et humains
JP2006514019A (ja) * 2002-11-27 2006-04-27 ケミン、インダストリーズ、インコーポレーテッド 動物及びヒト病原体に対して使用するためのバシラスサブティリス由来の抗菌化合物
EP1576120A4 (fr) * 2002-11-27 2006-06-07 Kemin Ind Inc Composes anti-microbiens issus de i bacillus subtilis /i et a utiliser contre des pathogenes animaux et humains
US7247299B2 (en) 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
WO2005007833A1 (fr) * 2003-07-17 2005-01-27 Charles Sturt University Isolat de souche de bacille a activite de suppression fongique
WO2017132230A1 (fr) * 2016-01-25 2017-08-03 Novozymes A/S Procédé pour réduire la prolifération microbienne dans un couvoir à volailles
US11395479B2 (en) 2016-01-25 2022-07-26 Novozymes A/S Method to reduce microbial bloom in poultry hatchery
WO2021234102A1 (fr) * 2020-05-20 2021-11-25 Nolivade Procédé de décontamination
FR3110344A1 (fr) * 2020-05-20 2021-11-26 Nolivade Procédé de décontamination

Also Published As

Publication number Publication date
AU1263199A (en) 1999-06-16

Similar Documents

Publication Publication Date Title
JP4623896B2 (ja) ヒトおよび動物に使用される細菌株、加工された植物抽出物およびプロバイオティック組成物
US7192581B2 (en) Lactobacillus reuteri useful as probiotics
JP4846795B2 (ja) プロバイオティック健康及び体調増進食品、餌及び／又は飲料水添加物並びにその使用
JP4410992B2 (ja) 細菌株、処理された植物抽出物、それらを含有する組成物、その調製方法、ならびにその治療的応用および産業的応用
JP2002523372A (ja) 共生乳酸産生細菌およびその使用
WO1989005849A1 (fr) Bacteries d'acide lactique destinees a etre utilisees dans des produits lactes fermentes et dans des preparations veterinaires
WO1994003195A1 (fr) Probiotique d'elimination de la salmonelle
RU2439145C2 (ru) Штамм микроорганизма bacillus smithii tbmi12 mscl p737 и применение его в качестве пищевой или кормовой добавки, или компонента пробиотической композиции и пробиотическая композиция
KR102391832B1 (ko) 클로스트리디오이데스 디피실 억제용 유산균 복합 균주 및 이를 포함하는 장염증 예방, 치료 또는 개선용 조성물
AU3472693A (en) Probiotic for control of salmonella
JPH11285378A (ja) 抗菌作用を有する新規枯草菌
JP5082048B2 (ja) 免疫賦活作用及び／又はアレルギー抑制作用を有し、且つ胃液耐性を有する新規乳酸菌
KR100443254B1 (ko) 내산성, 내담즙성 및 항생제 내성을 갖는 락토바실러스플란타룸
EP3741218A1 (fr) Souche de lactobacillus salivarus et son utilisation dans la prévention et le traitement de la diarrhée post-sevrage chez les porcelets
KR20170111763A (ko) 락토바실러스 애시도필러스 kcnu 균주를 유효성분으로 포함하는 클로스트리듐 디피실리에 의한 장 질환의 예방 또는 치료용 약제학적 조성물
CA2100774C (fr) Additif pour l'alimentation animale
KR100585391B1 (ko) 돼지 전염성위장염 (TGE) 코로나바이러스 및 유해 미생물 억제 활성을 갖는 신규 락토바실러스 프란타럼 Probio-38 및 이를 함유하는 생균활성제
KR100557397B1 (ko) 유해미생물 억제 활성을 가지는 신규 내산성 락토바실러스 루테리 Probio-054 및 이를 함유하는 생균활성제
KR100954882B1 (ko) 조류 인플루엔자 바이러스 감염억제 효과를 가지는 신규 유산균 및 이를 포함하는 조성물
JP2006169197A (ja) 家畜用抗菌剤及び飼料用組成物
KR102491640B1 (ko) 치아우식증 유발균을 억제하는 활성을 갖는 와이셀라 시바리아 균주 및 그 용도
WO1999028441A1 (fr) Nouvelle souche de bacillus subtilis avec effets antibacteriens
JP4509250B2 (ja) Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ除菌性医薬品
KR100513168B1 (ko) 돼지 유행성 설사증 (PED) 코로나바이러스 및 유해 미생물 억제 활성을 가지는 신규 내 산성 엔테로코커스 훼카리스Probio-056 및 이를 함유하는 생균활성제
KR100513167B1 (ko) 가금티푸스 유발 살모넬라 갈리나룸 및 유해 병원성 미생물 생육 억제능을 갖는 신규 내산성 엔테로코커스 훼칼리스 Probio-053 및 이를 함유한 생균활성제

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN KR NZ US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA